Canakinumab(ACZ885), human monoclonal antibody finds rejection as the advisors of the US Food and Drug Administration donot approve it for the treatment of gout.The Novartis drug Canakinumab got approval for the treatment of (CAPS-Cryopyrin periodic syndromes) by US FDA(June 2009) and by EMA(October 2009).Canakinumab(Ilaris) is a recombinant Interleukin-1 beta inhibitor.